Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) has announced a collaboration with TARA Mind, working alongside Veterans Exploring Treatment Solutions (VETS), to support clinical trial recruitment for its PARADIGM HLP003 Phase 3 program targeting major depressive disorder. The partnership aims to expand mental health awareness within the veteran community and aligns with the April 18, 2026 Executive Order on accelerating treatments for serious mental illness.
Helus Pharma is advancing its FDA Breakthrough Therapy-designated HLP003 program, a proprietary novel serotonergic agonist (NSA) in Phase 3 clinical development for the adjunctive treatment of major depressive disorder. The company also has HLP004, another proprietary NSA in Phase 2 for generalized anxiety disorder, and an extensive research portfolio of investigational NSAs.
The collaboration leverages the networks of TARA Mind and VETS to enhance veteran engagement in clinical trials. This is particularly significant given the high rates of mental health conditions among veterans, including depression and anxiety. By partnering with organizations that have direct access to this population, Helus Pharma aims to accelerate recruitment and ensure that the trial reflects the needs of those most affected.
The initiative comes in the wake of a recent Executive Order focused on accelerating treatments for serious mental illness, underscoring the national priority to address mental health crises. Helus Pharma's work with TARA Mind and VETS directly supports this goal by facilitating access to innovative therapies for veterans.
Helus Pharma, the commercial operating name of Cybin Inc., is a clinical stage pharmaceutical company committed to developing proprietary NSAs designed to activate serotonin pathways that promote neuroplasticity. The company's mission is to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions.
With class-leading data, Helus Pharma aims to improve the treatment landscape through NSAs that provide durable improvements in mental health. The Breakthrough Therapy designation from the U.S. Food and Drug Administration for HLP003 highlights the potential of this therapy to offer significant benefits over existing treatments.
The partnership with TARA Mind and VETS is a strategic move to ensure that the Phase 3 trial is well-subscribed and that the resulting data is robust. By focusing on veterans, Helus Pharma is also drawing attention to the mental health challenges faced by this group, which often go underreported and undertreated.
For more information about Helus Pharma and its pipeline, visit the company's website at www.helus.com. The latest news and updates relating to HELP are available in the company’s newsroom at https://ibn.fm/HELP.
